Japan Pharma Execs Say S. Korea Drug Makers Should Follow Their Model
This article was originally published in PharmAsia News
South Korea's pharmaceutical industry faces a need to change the way it does business as the government caps drug prices, and Daiichi Sankyo suggests following the Japanese business model.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.